Aethlon Medical
AEMD

$0.37

1.67%

Market Cap: 5.11M

About: Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.

Employees: 14

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0.11% less ownership

Funds ownership: 2.09% [Q4 2023] → 1.98% (-0.11%) [Q1 2024]

17% less funds holding

Funds holding: 12 [Q4 2023] → 10 (-2) [Q1 2024]

23% less capital invested

Capital invested by funds: $114K [Q4 2023] → $87.3K (-$26.4K) [Q1 2024]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$7

1,805%

upside

Avg. target

$8.50

2,213%

upside

High target

$10

2,621%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Vernon Bernardino	1,805%upside $7	Buy Maintained	24 Jun 2024
HC Wainwright & Co. Vernon Bernardino	2,621%upside $10	Buy Maintained	4 Mar 2024

See Analyst Rankings

Financial journalist opinion

Aethlon Medical, Inc. (AEMD) Q4 2024 Earnings Call Transcript

Aethlon Medical, Inc. (NASDAQ:AEMD ) Q4 2024 Earnings Conference Call June 27, 2024 4:30 PM ET Company Participants Michael Miller - Rx Communications, IR James Frakes - Interim CEO and CFO Steven LaRosa - Chief Medical Officer Conference Call Participants Marla Marin - Zacks Operator Good day and welcome to the Aethlon Medical Fiscal Year End of 2024 Earnings Conference Call. All participants will be in a listen-only mode.

Aethlon Medical, Inc. (AEMD) Q4 2024 Earnings Call Transcript

Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update

Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO , June 27, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal year ended March 31, 2024 and provided an update on recent developments.

Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update

Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024

SAN DIEGO , June 21, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal year ended March 31, 2024, at 4:15 p.m. ET on Thursday, June 27, 2024.

Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024

What's Next in Treatments for Cancer Patients with Solid Tumors?

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 20, 2024) - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at the future treatment of solid cancer tumors, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. Read the full article on Investorideas.com https://www.investorideas.com/News/2024/biotech/06200Treatments-for-Cancer-Patients-with-Solid-Tumors.asp Research released this year predicts, "The solid tumor therapeutics market size will grow from USD 222.71 Billion in 2023 to USD 885.44 Billion in 10 years.

What's Next in Treatments for Cancer Patients with Solid Tumors?

Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial

Aethlon Medical Granted Full Ethics Approval From the Human Research Ethics Committee at Central Adelaide Local Health Network for a Safety, Feasibility, and Dose Finding Study of its Hemopurifier® in Cancer Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO , June 18, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that, on June, 13, 2024, the Human Research Ethics Committee (HREC) of the Central Adelaide Local Health Network (CALHN) granted full ethics approval for Aethlon's safety, feasibility and dose-finding clinical trial of the Hemopurifier® in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The approval is valid for three years, until June 13, 2027.

Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial

The Hunt for Virus Treatments Continues Post Covid-19

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 7, 2024) - Investorideas.com, a go-to investing platform, releases the second of a two-part series looking at news and developments for the treatment of viruses, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. Read the full article on Investorideas.com https://www.investorideas.com/News/2024/biotech/06070Virus-Treatments-Post-Covid-19.asp The threat of viruses is back in the news with multiple news sources, including the Guardian reporting, "The World Health Organization (WHO) has said a man's death in Mexico was caused by a strain of bird flu called H5N2 that has never before been found in a human.

The Hunt for Virus Treatments Continues Post Covid-19

Why Is Aethlon Medical (AEMD) Stock Up 82% Today?

Aethlon Medical (NASDAQ: AEMD ) stock is soaring higher on Thursday alongside strong pre-market trading for the medical therapeutic company's shares. Aethlon Medical is experiencing heavy trading today with more than 26 million shares exchanging hands as of this writing.

Why Is Aethlon Medical (AEMD) Stock Up 82% Today?

Blood Purification Medical Devices Revolutionizing the Future of Health from Cancer to COVID

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 3, 2024) - Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at medical device advancements for blood purification, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. Read the full article on Investorideas.com https://www.investorideas.com/News/2024/biotech/06030Blood-Purification-Medical-Devices.asp According to Straits Research, "The global blood purification equipment market size was valued at USD 17,755.6 million in 2021.

Blood Purification Medical Devices Revolutionizing the Future of Health from Cancer to COVID

Aethlon Medical Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies

Phase 1 Clinical Trials of the Hemopurifier® Designed to Include Patients With Solid Tumors Who Have Stable or Progressive Disease During Anti-PD-1 Monotherapy Treatment, Such as Keytruda® of Opdivo® Interested Clinical Sites Have Initiated Submissions For Ethics Committee Review SAN DIEGO , June 3, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided the following update on its planned phase 1 safety, feasibility and dose-finding clinical trials of its Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®. "We continue to make progress preparing for our planned, safety, feasibility and "dose finding" oncology trials in Australia and India, and want to provide our shareholders and other constituents with an update, stated Steven LaRosa, MD, Chief Medical Officer of Aethlon Medical.

Aethlon Medical Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies

Aethlon Medical Announces Pricing of $4.7 Million Public Offering

SAN DIEGO , May 15, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the pricing of a public offering of an aggregate of 8,100,000 shares of its common stock (or pre-funded warrants in lieu thereof), Class A warrants to purchase up to 8,100,000 shares of common stock, and Class B warrants to purchase up to 8,100,000 shares of common stock, at a combined public offering price of $0.58 per share (or pre-funded warrant) and accompanying warrants. The warrants will have an exercise price of $0.58 per share, subject to an adjustment, will be exercisable immediately upon issuance and, in the case of Class A warrants, will expire on the fifth anniversary of the original issuance date, and in the case of Class B warrants, will expire on the one year anniversary of the original issuance date.

Aethlon Medical Announces Pricing of $4.7 Million Public Offering

See News Rankings